| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/0897190003259383 New Antiproliferative Immunosuppressive AgentsTransplant Pharmacokinetic Laboratory, Dumont-UCLA Transplant Center, 10833 LeConte Avenue, Room 77-120, Los Angeles, CA 90025 Since the early 1980s, the combination of cyclosporine, azathioprine, and prednisone has been the mainstay tripledrug immunosuppressive regimen used in transplantation. However, advances in drug research, design, and development have allowed for the introduction of new agents that have greatly increased the number of immunosuppressive agents available for use in transplant recipients. Particularly, the newer antiproliferative immunosuppressive drugs (agents that directly inhibit the proliferation of T and B lymphocytes) have had an important impact on patient outcomes posttransplant. These agents are mycophenolate mofetil and sirolimus.
Key Words: Mycophenolate mofetil sirolimus pharmacokinetics therapeutic drug monitoring drug interactions
|